Tsutomu Nakagawa
Direktor/Vorstandsmitglied bei SUMITOMO PHARMA CO., LTD.
Aktive Positionen von Tsutomu Nakagawa
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SUMITOMO PHARMA CO., LTD. | Direktor/Vorstandsmitglied | 25.06.2024 | - |
| Corporate Officer/Principal | 01.04.2016 | - | |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Direktor/Vorstandsmitglied | 01.07.2023 | - |
| Vorstandsvorsitzender | 01.04.2024 | - | |
| Präsident | 01.04.2024 | - | |
| Corporate Officer/Principal | 01.07.2023 | 01.04.2024 |
Karriereverlauf von Tsutomu Nakagawa
Statistik
International
| Vereinigte Staaten | 2 |
| Japan | 2 |
Operativ
| Director/Board Member | 2 |
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SUMITOMO PHARMA CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Health Technology |
- Börse
- Insiders
- Tsutomu Nakagawa
- Erfahrung
